Among 26 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 17 have Buy rating, 0 Sell and 9 Hold. Therefore 65% are positive. AstraZeneca plc (ADR) had 45 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Leerink Swann on Thursday, January 18 with “Hold”. The firm has “Buy” rating given on Monday, October 16 by Credit Suisse. Jefferies downgraded the stock to “Hold” rating in Tuesday, March 15 report. Credit Suisse downgraded AstraZeneca PLC (NYSE:AZN) on Tuesday, October 20 to “Underperform” rating. The firm has “Buy” rating by Liberum Capital given on Friday, November 25. The firm has “Market Perform” rating by Leerink Swann given on Monday, May 2. The firm has “Hold” rating by HBSC given on Monday, February 8. The stock has “Buy” rating by Citigroup on Wednesday, October 18. The firm has “Market Perform” rating by Leerink Swann given on Monday, October 23. The stock of AstraZeneca PLC (NYSE:AZN) has “Hold” rating given on Monday, April 10 by Jefferies. See AstraZeneca PLC (NYSE:AZN) latest ratings:
19/03/2018 Broker: Jefferies Old Rating: Hold New Rating: Buy Upgrade
06/02/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $36 New Target: $38 Maintain
05/02/2018 Broker: Bernstein Rating: Buy New Target: $42.0 Maintain
18/01/2018 Broker: Leerink Swann Rating: Hold New Target: $36.0 Maintain
29/12/2017 Broker: J.P. Morgan Rating: Buy Upgrade
29/12/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
23/10/2017 Broker: Leerink Swann Rating: Market Perform Old Target: $31 New Target: $34 Maintain
18/10/2017 Broker: Citigroup Rating: Buy Maintain
Canaccord Genuity currently has a $105.0000 PT on the $3.77 billion market cap company or 21.88% upside potential. In an analyst report sent to investors and clients on Monday morning, Blueprint Medicines (NASDAQ:BPMC) stock had its Buy Rating reconfirmed by expert analysts at Canaccord Genuity.
AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $86.96 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 30.08 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.
The stock decreased 1.87% or $0.68 during the last trading session, reaching $35.64. About 3.43 million shares traded. AstraZeneca PLC (NYSE:AZN) has risen 9.03% since April 16, 2017 and is uptrending. It has underperformed by 2.52% the S&P500.
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. The company has market cap of $3.77 billion. The Company’s lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It currently has negative earnings. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase and predicted NTRK resistant mutants.
Among 10 analysts covering Blueprint Medicine Corp (NASDAQ:BPMC), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicine Corp has $99.0 highest and $15 lowest target. $80.67’s average target is -6.36% below currents $86.145 stock price. Blueprint Medicine Corp had 23 analyst reports since February 22, 2016 according to SRatingsIntel. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) has “Buy” rating given on Monday, November 6 by Wedbush. The stock has “Buy” rating by Cowen & Co on Tuesday, June 6. BTIG Research maintained the shares of BPMC in report on Monday, November 13 with “Buy” rating. As per Friday, May 27, the company rating was initiated by Raymond James. The company was initiated on Friday, August 5 by Canaccord Genuity. The stock has “Overweight” rating by Morgan Stanley on Monday, October 23. The firm has “Buy” rating given on Friday, December 22 by Jefferies. The rating was maintained by Canaccord Genuity on Wednesday, September 20 with “Buy”. On Monday, December 11 the stock rating was upgraded by Goldman Sachs to “Buy”. The firm earned “Buy” rating on Tuesday, October 31 by BTIG Research.